摘要
类风湿性关节炎(RA)是一种已知的慢性自身免疫性疾病,可引起关节畸形甚至关节功能丧失。中药在治疗骨科慢性疾病中具有显著作用。据报道,中药及其有效成分通过信号通路是治疗RA的重要途径。因此,本文回顾了目前可用的关于中药对RA治疗作用的参考文献,并总结了相关的信号通路,主要相关信号通路归纳为TLR4/MAPK/NF-κB信号通路,Wnt/β-catenin信号通路,OPG/RANKL/RANK信号通路,PI3K-Akt介导的细胞凋亡通路以及janus激酶/信号转导和转录激活因子(JAK-STAT)信号通路。了解这些中药在RA中的作用途径,不仅有助于阐明中药治疗RA的分子机制,也有利于从天然草药中寻找新的候选治疗药物。
Rheumatoid arthritis(RA)is a known chronic autoimmune disease that can cause joint deformities and even loss of joint function.Chinese medicine plays a significant role in the treatment of chronic orthopaedic diseases.According to reports,traditional Chinese medicine and its active in‐gredients through the signaling pathway is an important way to treat RA.Therefore,this paper reviewed the currently available references on the therapeutic effects of traditional Chinese medicine on RA,and summarized the relevant signaling pathways.The main relevant signaling pathways were summarized as TLR4/MAPK/NF-κB signaling pathway,Wnt/β-catenin signaling pathway,OPG/RANKL/RANK signaling pathway,and WNT/RANKL signaling pathway.Pi3k-akt-mediated apoptosis pathway and Janus kinase/Signal transduction and Activator of Transcription(JAK-STAT)signaling pathway.Understanding the pathways of action of these Chinese medicines in RA is not only helpful to elucidate the molecular mechanism of Chinese medicines in the treatment of RA,but also conducive to finding new candidate therapeutic drugs from natural herbs.
作者
安文博
刘建军
张晓刚
左利平
陈一新
陈欣
齐鑫
南瑞雄
AN Wenbo;LIU Jianjun;ZHANG Xiaogang;ZUO Liping;CHEN Yixin;CHEN Xin;QI Xin;NAN Ruixiong(Affiliated Hospital of Gansu University of Traditional Chinese Medicine,Lanzhou,Gansu 730000;Gansu University of Traditional Chinese Medicine,Lanzhou,Gansu 730000;Lanzhou First People's Hospital,Lanzhou,Gansu 730000)
出处
《中医康复》
2024年第10期41-47,共7页
Traditional Chinese Medicine Rehabilitation
基金
张晓刚全国名老中医药专家传承工作室建设项目(国中医药人教函2022-75号)
2022年甘肃省自然科学基金(22JR11RA126)
2023年省级重点人才项目(002087001,2060208)
国家中医骨伤优势专科项目(2023GS-02,2023GS-08)
2021兰州市科技局指导性计划项目(2022-ZD-91)
甘肃省中医药科研课题(GZKZ-2022-4)
兰州市科技局社会发展科技科(2023-ZD-144)
2020院内创新基金(gzfy-2020-27)。